Trial Profile
A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms A-taxel
- 09 Jan 2014 According to ClinicalTrials.gov [NCT01069796] planned end Date changed from 1 Dec 2015 to 1 Jun 2014.
- 09 Jan 2014 According to ClinicalTrials.gov [NCT01069796] study status changed to discontinued.
- 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.